🔬A highly interesting research poster presented at the #ECCO2025 conference in Berlin this year by Van der Kruk et al. highlighted microbially conjugated #bileacids (MCBAs) as potential biomarkers for dietary therapy outcomes in pediatric patients with #crohnsdisease. 1/
Our April issue is here..and that's no joke! Featuring new AGA clinical guidance on HBVr, studies in subcutaneous gudelkumab from #ECCO2025, and more. ow.ly/SPMW50VsEVz
It was a pleasure to present our collaboration with PREDICT at #ECCO2025 last week. We demonstrate subgroups of IBD patients can be characterised by distinct FC and CRP profiles, validated independently in 🇩🇰. The preprint is available here: doi.org/10.1101/2024...
Digestive functional outcomes after primary ileocecal resection for Crohn’s disease. Data from Saint-Antoine Hospital
#ECCO2025
@aphp.bsky.social
@Jérémie Lefèvre
@Julien Kirchgesner
@Philippe Seksik
@Saint-Antoine IBD Network
@h-sokol.bsky.social
Unique hyperinflammatory macrophages on the same time slams on the 'brakes' #ACOD1 in #Crohns beautifully presented by Gareth Jones #ECCO2025 in Berlin. #macrophages
Biology is just so interesting @uofgsii.bsky.social @gastrogrj.bsky.social @bainlab.bsky.social
East-West connection made with China Crohn's & Colitis Foundation in #ECCO2025 Berlin! ✨️ #IBD #China #Crohn's
REScUE trial of patients with CD losing response to UST
All patients received IV reinduction and then q4w SC vs q8w SC
❗️Primary outcome: SF clinical remission: PRO2 & FCP <250 & no steroids for 90 days before w48
‼️Less than 20% met primary outcome
#ECCO2025
Clusters of antibiotic use patterns after the first episode of pouchitis
4⃣ groups: rare intermittent > intermittent > chronic antibiotic-responsive > chronic antibiotic dependent
antiTNF prior IPAA & antibióticos in the 12 months prior pouch formation associated with chronic pouchitis
#ECCO2025
Phase 1b study of SOR102, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in mild to
severe UC
!! Phase 1b very small N so caution with interpretation
It surprised me the fact that it includes also patients with mild #UC? giving a double acting
#IBD #ECCO2025
Duvakitug (TEV-48574) Anti-TL1A- RELIEVE UCCD trial
Results from a Phase 2b trial
#IBD #CD #ECCO2025
Serum IL-6 likely picking out the JAKi responders in ASUC #IBD
Stool TNF early, and TNF staying up by d3 - time to move on from steroids/TNF
#ECCO2025
Are we approaching a ONE biologic -> JAKi era? #ECCO2025
In the US for sick #IBD patients, that means biosim IFX (or IFX/Aza) then Upa (or tofa when generic in 2026).
This is the route to get to JAKi fastest.
If the patient is less sick
biosim Uste/Vedo/Risa -> IFX -> Upa/Tofa may be the way
Well, that never worked.
Even the Takeda folks knew it was a dry well.
More is not always better.
If Vedo is not working, move on in #IBD.
#ECCO2025
@bealoquebea.bsky.social
Great session on Sustainability in IBD at #ECCO2025, it was an honor to present our UEG Green Paper followed by an excellent overview of Green Endoscopy by Shaji Sebastian.
Link to our full paper published in @UEGJournal onlinelibrary.wiley.com/doi/full/10.10…
Excited to share our work on UC cytokine networks at #ECCO2025.
Come by poster P0104 if you are interested in:
- how cytokines regulate each other in UC
- the role of TL1A in treatment-naive UC
- how we could use this approach to identify new drug targets
www.biorxiv.org/content/10.1...
Plenty of discussion at #ECCO2025 on opportunities for AI in IBD care. But how do the vast electricity/water requirements of AI servers fit our #sustainability aims? Are there offsets we can make? Can we justify the data storage requirements of continuous monitoring?
Great effort by Duncan at ECCO meeting, Berlin. In UC gut stem cells, not only is there mitochondrial dysfunction (power failure) but loss of ketogenesis (backup power) is the critical tipping point. #mitochondria #ketogenic #ECCO2025 #colitis #stemcells #ibd Proud supervisor
Dr. Derikx presenting data from @predicct :
-psychosocial factors are associated with flares in IBD
-anxiety, sleep, and somatization were associated w clinical flare in IBD
-depression and ⬇️exercise was associated with hard flares in those w UC/IBDU
#ECCO25 #ECCO2025
@doc_ibd speaking at #ECCO25 on development of a new classification (Florence) for all IBD. Incredible work by a strong group! @IBDCedarsSinai #ECCO2025 @espghansociety.bsky.social @ioibd
if you are today at #ECCO2025 It’ll be difficult to miss out this talk by @bradleyomics.bsky.social
presenting the work by both super ⭐️ Dr Harris and Dr Alegbe
This large dataset will be key to better understand the biology of IBD susceptibility mediated by genetics
Logo by Dr Harriet Banks
🚨 Kicking off #ECCO2025 with a great ClinCom session led by @J_Kirchgesner
Fantastic talks and amazing people 🙏🏽
None better than @ibdseb.bsky.social to talk about underrepresented populations in #IBD research #ECCO2025
Difficult to choose the best slides, thanks Seb
School for Clinical trialist #ECCO2025
Starting by @J_Kirchgesner introducing how to set your path from the early days #ibd
How to create a global consortium by
@DrAilsaHart at #ECCO2025
Huge expertise with the perianal disease consortium
Great to see how this has progressed from the first idea #ibd
CJ Bioscience to Showcase Preclinical Data for CJRB-201 at ECCO 2025 #South_Korea #Seoul #CJRB-201 #CJ_Broscience #ECCO2025
